8-K filing — ELUTIA INC. (ELUT)
Filed: 2026-08-21 AccNo: 0001104659-26-099731 Size: 644 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Elutia To Sell SimpliDerm Business To Cellution Biologics For Up To $11M
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Elutia Q2 2026 Earnings Call Transcript
On Thursday, Elutia (NASDAQ:ELUT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to
Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028
Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate
Elutia (NASDAQ:ELUT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the